发明名称 |
Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases |
摘要 |
Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.;wherein R1 through R8 and n are as defined in this disclosure. |
申请公布号 |
US9066922(B2) |
申请公布日期 |
2015.06.30 |
申请号 |
US201313870350 |
申请日期 |
2013.04.25 |
申请人 |
MD BIOALPHA CO., LTD.;KT & G CO., LTD. |
发明人 |
Yoo Sang-Ku;Park Myunggyu;Jo In Geun;Kwak Taehwan |
分类号 |
A01N43/00;A61K31/33;A01N43/16;A61K31/35;A61K31/352;A61K31/343;A61K31/353;A61K31/453 |
主分类号 |
A01N43/00 |
代理机构 |
Birch, Stewart, Kolasch & Birch, LLP |
代理人 |
Birch, Stewart, Kolasch & Birch, LLP |
主权项 |
1. A method of treating a liver disease, comprising
administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound represented by Formula I: wherein R1 and R2 are each independently hydrogen, halogen, alkoxy, hydroxy or lower alkyl having 1 to 6 carbon atoms; R3, R4, R5, R6, R7 and R8 are each independently hydrogen, hydroxy, C1-C20 alkyl, alkene or alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or two substituents of R3 to R8 may be taken together to form a cyclic structure; and n is 0 or 1, with proviso that when n is 0, carbon atoms adjacent to n form a cyclic structure via a direct bond; or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof, wherein the liver disease is selected from the group consisting of a fatty liver, hepatic failure, liver function failure, and hepatomegaly. |
地址 |
Daejeon KR |